SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: July 23, 2002
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation plc restructures loan with Elan.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: July 23, 2002
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Amarin Corporation plc restructures
Loan with Elan.
Exhibit
(a)
Contacts:
Rick Stewart Nigel Bell
Chief Executive Officer Chief Financial Officer
Amarin Corporation plc Amarin Corporation plc
Phone: +44 (0) 207 907 2440 Phone: +44 (0) 207 907 2444
Email: rick.stewart@amarincorp.com Email: nigel.bell@amarincorp.com
AMARIN CORPORATION RESTRUCTURES
LOAN AGREEMENT WITH ELAN
London, United Kingdom, July 23, 2002 -- Amarin Corporation plc (NASDAQ: AMRN)
today announced that it has restructured a $45 million loan from Elan
Pharmaceuticals, Inc. originally scheduled for repayment in full on September
30, 2002. Under the revised payment schedule, the loan will be repaid in three
annual instalments of $20 million, $10 million and $15 million, beginning in
the third quarter of this year, 2002. Interest will continue to accrue and
will also be paid annually. The obligation was incurred last year as part of
Amarin's acquisition of marketing and purchase option rights to Permax(r)
(pergolide mesylate), a dopamine receptor agonist indicated as adjunctive
therapy in the management of Parkinson's disease. Amarin is the exclusive
licensee for Permax in the United States.
"We are very pleased to have successfully completed the restructuring of this
loan agreement," said Rick Stewart, chief executive officer. "Extending the
loan repayment now permits us to better direct resources toward advancing our
late stage product opportunities. These include preparing for the launch of
Zelapar ( tm ) upon approval by FDA."
Zelapar (selegiline HCl orally dissolving tablets), an MAO-B inhibitor, is
being developed as adjunctive therapy to levodopa for treatment of the symptoms
of Parkinson's disease. Last May, the U.S. Food and Drug Administration
accepted for filing and review the New Drug Application for Zelapar.
Permax is generally well tolerated. The most commonly reported side effects
are nausea, somnolence, dizziness, headache and dyskinesia. Full prescribing
information for Permax is available from Amarin upon request, or can be found
at www.amarinpharma.com, the website of Amarin Pharmaceuticals, Inc., the
Company's drug development and marketing subsidiary.
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology and pain management. The Company plans to become a leader in these
therapeutic categories by providing innovative products and solutions that
address significant unmet medical needs.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from any
performance suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development and commercialisation, FDA approval, the impact
of competitive products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more information, please
refer to Amarin Corporation's Annual Report for 2001 on Form 20-F and its Form
6-Ks as filed with the U.S. Securities and Exchange Commission. The company
assumes no obligation to update information on its expectations.